{
  "id": 7671395,
  "title": "Oruka Therapeutics chief medical officer Joana Goncalves sells $734k in shares",
  "url": "https://urgent.news/2026/09/16/oruka-therapeutics-chief-medical-officer-joana-goncalves-sells-734k",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-16T01:01:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/oruka-therapeutics-chief-medical-officer-joana-goncalves-sells-734k-in-shares-93CH-4902810"
  },
  "original_language": "en",
  "account": "Joana Goncalves, Chief Medical Officer at Oruka Therapeutics, sold 7,947 shares of the company's common stock on September 15, 2026, for about $734,144. The biotech firm's shares were trading at $92.20, up 518% over the past year, but analysts consider it overvalued. The sale followed the exercise of employee stock options and warrants. Most of the shares were sold via a Rule 10b5-1 trading plan, with prices ranging from $91.10 to $94.22. Ms. Goncalves used part of the proceeds to cover tax obligations from restricted stock units, selling the remaining 947 shares at $95.71. Before selling, she bought 7,000 shares using options and warrants, which she exercised on the same day. These options and warrants had prices between $6.84 and $7.80, valued at about $51,240. After the reported transactions, Ms. Goncalves directly owns 31,771 shares and also holds 193,563 employee stock options and 164,992 employee warrants. Oruka Therapeutics has a market capitalization of $6.35 billion, but it is still not profitable. Analysts predict a bullish outlook for the company, with price targets ranging from $117 to $200.",
  "summary": null,
  "key_points": [
    "Joana Goncalves, Oruka Therapeutics CMO, sold 7,947 shares on September 15, 2026.",
    "Sale price was $734,144, shares traded at $92.20, up 518% year-over-year.",
    "Goncalves used proceeds to cover tax obligations on restricted stock units."
  ],
  "editors_take": "The sale of nearly $734,000 in shares by Oruka Therapeutics' chief medical officer suggests insiders may be taking advantage of the stock's 518% surge in value over the past year.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Tenax Therapeutics CEO Christopher Giordano acquires $20,087 in shares",
        "url": "https://urgent.news/2026/09/16/tenax-therapeutics-ceo-christopher-giordano-acquires-20-087-in-shares",
        "published": "2026-09-16T03:01:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}